Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

2.

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.

Korenblat P, Kerwin E, Leshchenko I, Yen K, Holweg CTJ, Anzures-Cabrera J, Martin C, Putnam WS, Governale L, Olsson J, Matthews JG.

Respir Med. 2018 Jan;134:143-149. doi: 10.1016/j.rmed.2017.12.006. Epub 2017 Dec 13.

3.

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.

Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, Anzures-Cabrera J, Lehnert V, Pauly-Evers M, Holme I, Štásek J, van Hessen MW, Jones P; dal-ACUTE Investigators.

Eur Heart J. 2014 Jul 14;35(27):1792-800. doi: 10.1093/eurheartj/ehu105. Epub 2014 Mar 17.

PMID:
24639426
4.

A tool to assess the quality of a meta-analysis.

Higgins JP, Lane PW, Anagnostelis B, Anzures-Cabrera J, Baker NF, Cappelleri JC, Haughie S, Hollis S, Lewis SC, Moneuse P, Whitehead A.

Res Synth Methods. 2013 Dec;4(4):351-66. doi: 10.1002/jrsm.1092. Epub 2013 Oct 18.

PMID:
26053948
5.

Methodological quality of meta-analyses: matched-pairs comparison over time and between industry-sponsored and academic-sponsored reports.

Lane PW, Higgins JP, Anagnostelis B, Anzures-Cabrera J, Baker NF, Cappelleri JC, Haughie S, Hollis S, Lewis SC, Moneuse P, Whitehead A.

Res Synth Methods. 2013 Dec;4(4):342-50. doi: 10.1002/jrsm.1072. Epub 2013 Oct 18.

PMID:
26053947
6.

Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?

Phelan M, Anzures-Cabrera J, Carlile DJ, Rowell L, Kuhlmann O, Arold G, Robson R, Bentley D.

Clin Pharmacokinet. 2013 Apr;52(4):255-65. doi: 10.1007/s40262-013-0035-z.

PMID:
23400900
7.

In vivo evaluation of drug-drug interactions linked to UGT inhibition: the effect of probenecid on dalcetrapib pharmacokinetics.

Aceves Baldó P, Anzures-Cabrera J, Bentley D.

Int J Clin Pharmacol Ther. 2013 Mar;51(3):215-8. doi: 10.5414/CP201766.

PMID:
23357838
8.

WITHDRAWN: Opioids for the palliation of breathlessness in advanced disease and terminal illness.

Jennings AL, Davies AN, Higgins JP, Anzures-Cabrera J, Broadley KE.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002066. doi: 10.1002/14651858.CD002066.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;(7):CD002066.

PMID:
22786477
9.
10.

Expressing findings from meta-analyses of continuous outcomes in terms of risks.

Anzures-Cabrera J, Sarpatwari A, Higgins JP.

Stat Med. 2011 Nov 10;30(25):2967-85. doi: 10.1002/sim.4298. Epub 2011 Aug 8.

PMID:
21826697
11.

Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.

Derks M, Anzures-Cabrera J, Turnbull L, Phelan M.

Clin Drug Investig. 2011;31(5):325-35. doi: 10.2165/11533550-000000000-00000.

PMID:
21366361
12.

Graphical displays for meta-analysis: An overview with suggestions for practice.

Anzures-Cabrera J, Higgins JP.

Res Synth Methods. 2010 Jan;1(1):66-80. doi: 10.1002/jrsm.6. Epub 2010 Mar 23.

PMID:
26056093
13.

Meta-analysis of skewed data: combining results reported on log-transformed or raw scales.

Higgins JP, White IR, Anzures-Cabrera J.

Stat Med. 2008 Dec 20;27(29):6072-92. doi: 10.1002/sim.3427.

Supplemental Content

Loading ...
Support Center